Coherus Oncology, Inc.
CHRS
$1.22
$0.065.17%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.57M | 10.25M | 7.60M | 54.14M | 6.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.57M | 10.25M | 7.60M | 54.14M | 6.05M |
| Cost of Revenue | 3.72M | 3.40M | 2.65M | 33.86M | 2.73M |
| Gross Profit | 7.85M | 6.86M | 4.95M | 20.29M | 3.32M |
| SG&A Expenses | 22.83M | 26.04M | 26.03M | 34.60M | 28.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.80M | 55.74M | 53.03M | 89.69M | 52.91M |
| Operating Income | -42.23M | -45.49M | -45.44M | -35.55M | -46.86M |
| Income Before Tax | -44.52M | -44.86M | -47.40M | -50.70M | -47.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.52M | -44.86M | -47.40M | -50.70M | -47.60M |
| Earnings from Discontinued Operations | 8.99M | 342.63M | -9.17M | -- | 36.85M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.53M | 297.77M | -56.57M | -50.70M | -10.75M |
| EBIT | -42.23M | -45.49M | -45.44M | -35.55M | -46.86M |
| EBITDA | -41.27M | -44.47M | -44.39M | -34.51M | -45.31M |
| EPS Basic | -0.31 | 2.57 | -0.49 | -0.44 | -0.09 |
| Normalized Basic EPS | -0.23 | -0.24 | -0.26 | -1.19 | -0.26 |
| EPS Diluted | -0.31 | 2.57 | -0.49 | -0.47 | -0.09 |
| Normalized Diluted EPS | -0.23 | -0.24 | -0.26 | -1.19 | -0.26 |
| Average Basic Shares Outstanding | 116.23M | 116.08M | 115.86M | 115.42M | 115.21M |
| Average Diluted Shares Outstanding | 116.23M | 116.08M | 115.86M | 115.42M | 115.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |